The U.S. nanomedicine market size was exhibited at USD 91.35 billion in 2023 and is projected to hit around USD 279.69 billion by 2033, growing at a CAGR of 11.84% during the forecast period 2024 to 2033.
| Report Coverage | Details |
| Market Size in 2024 | USD 102.17 Billion |
| Market Size by 2033 | USD 279.69 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 11.84% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Application, Indication, Molecule Type |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | U.S. |
| Key Companies Profiled | Abbott Laboratories; CombiMatrix Corporation; Celgene Corporation; Nanospectra Biosciences, Inc.; GE Healthcare; Johnson & Johnson Services, Inc.; Mallinckrodt Pharmaceuticals; Merck & Co., Inc.; Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Arrowhead Pharmaceuticals, Inc. |
owing to the presence of substantial players involved in development and manufacturing of nanomedicine for various therapeutic fields. Moreover, rising cases of disease-related morbidity and mortality in the country have accentuated the need to develop more robust therapies, thereby driving growth of the market
U.S. accounted for 48% of the global nanomedicine market in 2023. The funding bodies have played a major role in reshaping the market. Government has made huge investments to accelerate nanoscience R&D in this arena. For instance, in August 2020, the National Science Foundation declared that it would invest a huge amount of USD 84 million over five years for the re-establishment of National Nanotechnology Coordinated Infrastructure to bring further advancements in nanoscale engineering, science, and technology.
Furthermore, the presence of organizations involved in conducting conferences and workshops for growing awareness about the application of nanoscience in therapeutic development is expected to accelerate the market growth in this country in the coming years. For instance, the American Society for Nanomedicine is involved in conducting quarterly conferences on nanoscience and nanomedicine.
Moreover, developed infrastructure, and growing popularity of nanoparticle-based drugs in the country are driving the nanomedicine market. An increase in nanomedicine R&D in the country owing to rising funds and investments from small & medium-sized enterprises and other venture funds is the high impact-rendering driver for the market in this country.
The drug delivery segment dominated the market with a share of 34% in 2023. The rising adoption of metal-based nanoparticles for biomedical applications is expected to contribute to market growth. Furthermore, growing interest in vivo-specific targeting of gold-based drug delivery for larger sizes of conjugates is projected to drive the demand for segment. Ongoing research on drug delivery applications with the usage of gold and other metal and metal oxide nanoparticles in combination with their intrinsic ability for photothermal therapy, is anticipated to boost the segment’s rapid growth.
The therapeutics segment is expected to witness highest growth over the forecast period. Advancements in the field of nanotherapeutics development related to crossing biological barriers are projected to drive market growth over the forecast period. Nanotherapeutics with multiple advantages are expected to aid in addressing the existing gaps in the current field of therapeutics. Blood disorders, diabetes, cancer, and neurodegenerative diseases are some of the therapeutic areas that are anticipated to benefit from nano-based drug delivery systems
The clinical oncology segment dominated the market with a share of 33% in 2023. This can be attributed to cancer being a leading cause of mortality and morbidity. The need for developing more targeted cancer therapies is a key factor expected to drive R&D for clinical oncology. Nanomedicine is a rapidly evolving treatment modality owing to its targeting efficiency and fewer adverse effects in cancer treatment. Research in Cancer Nanotechnology (IRCN) is also expected to further enhance the segment’s growth.
The infectious disease segment is expected to register considerable growth over the forecast period. Application of nanoparticle-based therapies for targeting non-cancer conditions such as infectious diseases has increased in recent years. Ongoing R&D to develop solutions to address the increasing infectious diseases burden is another key factor expected to propel growth of nanomedicine market over the forecast period.
The nanoparticles segment dominated the market with a share of 76.15% in 2023. Studies are conducted to assess ongoing advancements in drug delivery of targeted nanoparticles to treat melanoma. Moreover, several research projects are carried out to study nanoparticle implementation in homeopathy. Such factors are expected to boost the segment’s growth in the upcoming years.
The nanoparticles segment is expected to register a considerable CAGR over the forecast period. Nanoparticles offer several advantages over conventional molecular imaging probes. Nanotubes are used in designing strategies for delivering genes & molecular probes and pharmaceuticals into cells. They also play a pivotal role in stem cell therapies and aid in tissue regeneration. Carbon nanotubes have received great attention as carriers of biologically relevant molecules due to their unique chemical, physical, and physiological properties.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. nanomedicine market
Application Scope
Indication Scope
Molecule Type Scope
Chapter 1. Nanomedicine Market: Methodology and Scope
1.1. Information Procurement
1.2. Information Or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Nanomedicine Market: Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Nanomedicine Market: Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising Level Of Government Participation In R&D Funding
3.2.1.2. Introduction Of Technological Advancements In Diagnostic Procedures
3.2.1.3. Rising Usage Of Nanomedicine In Drug Delivery Technology
3.2.2. Market Restraint Analysis
3.2.2.1. Side Effects Associated With Intake Of Nanoparticles And Lower Adoption Rate By Patients
3.2.2.2. Limited Adoption By Medical And Pharmaceutical Industry
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Application Business Analysis
4.1. Nanomedicine Market: Application Movement Analysis
4.2. Therapeutics
4.2.1. Therapeutics Market, 2021 - 2033
4.3. In-vitro Diagnostics
4.3.1. In-vitro Diagnostics Market, 2021 - 2033
4.4. Drug Delivery
4.4.1. Drug Delivery Market, 2021 - 2033
4.5. In-vivo Imaging
4.5.1. In-vivo Imaging Market, 2021 - 2033
4.6. Implants
4.6.1. Implants Market, 2021 - 2033
Chapter 5. Indication Business Analysis
5.1. Nanomedicine Market: Indication Movement Analysis
5.2. Clinical Oncology
5.2.1. Clinical Oncology Market, 2021 - 2033
5.3. Infectious Diseases
5.3.1. Infectious Diseases Market, 2021 - 2033
5.4. Clinical Cardiology
5.4.1. Clinical Cardiology Market, 2021 - 2033
5.5. Orthopedics
5.5.1. Orthopedics Market, 2021 - 2033
5.6. Others
5.6.1. Other Indications Market, 2021 - 2033
Chapter 6. Molecule Type Business Analysis
6.1. Nanomedicine Market: Molecule Type Movement Analysis
6.2. Nanoparticles
6.2.1. Nanoparticles Market, 2021 - 2033
6.2.2. Metal & Metal Oxide Nanoparticles
6.2.2.1. Metal & Metal Oxide Nanoparticles Market, 2021 - 2033
6.2.3. Liposomes
6.2.3.1. Liposomes Market, 2021 - 2033
6.2.4. Polymers & Polymer Drug Conjugates
6.2.4.1. Polymers & Polymer Drug Conjugates Market, 2021 - 2033
6.2.5. Hydrogel Nanoparticles
6.2.5.1. Hydrogel Nanoparticles Market, 2021 - 2033
6.2.6. Dendrimers
6.2.6.1. Dendrimers Market, 2021 - 2033
6.2.7. Inorganic Nanoparticles
6.2.7.1. Inorganic Nanoparticles Market, 2021 - 2033
6.3. Nanoshells
6.3.1. Nanoshells Market, 2021 - 2033
6.4. Nanotubes
6.4.1. Nanotubes Market, 2021 - 2033
6.5. Nanodevices
6.5.1. Nanodevices Market, 2021 - 2033
Chapter 7. Regional Business Analysis
7.1. Nanomedicine Market Share By Region, 2024 & 2033
7.2. North America
7.2.1. SWOT Analysis
7.2.2. North America Nanomedicine Market, 2021 - 2033
7.2.3. U.S.
7.2.3.1. Key Country Dynamics
7.2.3.2. Target Disease Prevalence
7.2.3.3. Competitive Scenario
7.2.3.4. Regulatory Framework
7.2.3.5. Reimbursement Scenario
7.2.3.6. U.S. Nanomedicine Market, 2021 - 2033
7.2.4. Canada
7.2.4.1. Key Country Dynamics
7.2.4.2. Target Disease Prevalence
7.2.4.3. Competitive Scenario
7.2.4.4. Regulatory Framework
7.2.4.5. Reimbursement Scenario
7.2.4.6. Canada Nanomedicine Market, 2021 - 2033
7.3. Europe
7.3.1. SWOT Analysis
7.3.2. Europe Nanomedicine Market, 2021 - 2033
7.3.3. UK
7.3.3.1. Key Country Dynamics
7.3.3.2. Target Disease Prevalence
7.3.3.3. Competitive Scenario
7.3.3.4. Regulatory Framework
7.3.3.5. Reimbursement Scenario
7.3.3.6. UK Nanomedicine Market, 2021 - 2033
7.3.4. Germany
7.3.4.1. Key Country Dynamics
7.3.4.2. Target Disease Prevalence
7.3.4.3. Competitive Scenario
7.3.4.4. Regulatory Framework
7.3.4.5. Reimbursement Scenario
7.3.4.6. Germany Nanomedicine Market, 2021 - 2033
7.3.5. France
7.3.5.1. Key Country Dynamics
7.3.5.2. Target Disease Prevalence
7.3.5.3. Competitive Scenario
7.3.5.4. Regulatory Framework
7.3.5.5. Reimbursement Scenario
7.3.5.6. France Nanomedicine Market, 2021 - 2033
7.3.6. Italy
7.3.6.1. Key Country Dynamics
7.3.6.2. Target Disease Prevalence
7.3.6.3. Competitive Scenario
7.3.6.4. Regulatory Framework
7.3.6.5. Reimbursement Scenario
7.3.6.6. Italy Nanomedicine Market, 2021 - 2033
7.3.7. Spain
7.3.7.1. Key Country Dynamics
7.3.7.2. Target Disease Prevalence
7.3.7.3. Competitive Scenario
7.3.7.4. Regulatory Framework
7.3.7.5. Reimbursement Scenario
7.3.7.6. Spain Nanomedicine Market, 2021 - 2033
7.3.8. Denmark
7.3.8.1. Key Country Dynamics
7.3.8.2. Target Disease Prevalence
7.3.8.3. Competitive Scenario
7.3.8.4. Regulatory Framework
7.3.8.5. Reimbursement Scenario
7.3.8.6. Denmark Nanomedicine Market, 2021 - 2033
7.3.9. Sweden
7.3.9.1. Key Country Dynamics
7.3.9.2. Target Disease Prevalence
7.3.9.3. Competitive Scenario
7.3.9.4. Regulatory Framework
7.3.9.5. Reimbursement Scenario
7.3.9.6. Sweden Nanomedicine Market, 2021 - 2033
7.3.10. Norway
7.3.10.1. Key Country Dynamics
7.3.10.2. Target Disease Prevalence
7.3.10.3. Competitive Scenario
7.3.10.4. Regulatory Framework
7.3.10.5. Reimbursement Scenario
7.3.10.6. Norway Nanomedicine Market, 2021 - 2033
7.4. Asia Pacific
7.4.1. SWOT Analysis
7.4.2. Asia Pacific Nanomedicine Market, 2021 - 2033
7.4.3. Japan
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Competitive Scenario
7.4.3.4. Regulatory Framework
7.4.3.5. Reimbursement Scenario
7.4.3.6. Japan Nanomedicine Market, 2021 - 2033
7.4.4. China
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Competitive Scenario
7.4.4.4. Regulatory Framework
7.4.4.5. Reimbursement Scenario
7.4.4.6. China Nanomedicine Market, 2021 - 2033
7.4.5. India
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Competitive Scenario
7.4.5.4. Regulatory Framework
7.4.5.5. Reimbursement Scenario
7.4.5.6. India Nanomedicine Market, 2021 - 2033
7.4.6. Australia
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Competitive Scenario
7.4.6.4. Regulatory Framework
7.4.6.5. Reimbursement Scenario
7.4.6.6. Australia Nanomedicine Market, 2021 - 2033
7.4.7. Thailand
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Competitive Scenario
7.4.7.4. Regulatory Framework
7.4.7.5. Reimbursement Scenario
7.4.7.6. Thailand Nanomedicine Market, 2021 - 2033
7.4.8. South Korea
7.4.8.1. Key Country Dynamics
7.4.8.2. Target Disease Prevalence
7.4.8.3. Competitive Scenario
7.4.8.4. Regulatory Framework
7.4.8.5. Reimbursement Scenario
7.4.8.6. South Korea Nanomedicine Market, 2021 - 2033
7.5. Latin America
7.5.1. SWOT Analysis
7.5.2. Latin America Nanomedicine Market, 2021 - 2033
7.5.3. Brazil
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Competitive Scenario
7.5.3.4. Regulatory Framework
7.5.3.5. Reimbursement Scenario
7.5.3.6. Brazil Nanomedicine Market, 2021 - 2033
7.5.4. Mexico
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Competitive Scenario
7.5.4.4. Regulatory Framework
7.5.4.5. Reimbursement Scenario
7.5.4.6. Mexico Nanomedicine Market, 2021 - 2033
7.5.5. Argentina
7.5.5.1. Key Country Dynamics
7.5.5.2. Target Disease Prevalence
7.5.5.3. Competitive Scenario
7.5.5.4. Regulatory Framework
7.5.5.5. Reimbursement Scenario
7.5.5.6. Argentina Nanomedicine Market, 2021 - 2033
7.6. MEA
7.6.1. SWOT Analysis
7.6.2. MEA Nanomedicine Market, 2021 - 2033
7.6.3. South Africa
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Competitive Scenario
7.6.3.4. Regulatory Framework
7.6.3.5. Reimbursement Scenario
7.6.3.6. South Africa Nanomedicine Market, 2021 - 2033
7.6.4. Saudi Arabia
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Competitive Scenario
7.6.4.4. Regulatory Framework
7.6.4.5. Reimbursement Scenario
7.6.4.6. Saudi Arabia Nanomedicine Market, 2021 - 2033
7.6.5. UAE
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Competitive Scenario
7.6.5.4. Regulatory Framework
7.6.5.5. Reimbursement Scenario
7.6.5.6. UAE Nanomedicine Market, 2021 - 2033
7.6.6. Kuwait
7.6.6.1. Key Country Dynamics
7.6.6.2. Target Disease Prevalence
7.6.6.3. Competitive Scenario
7.6.6.4. Regulatory Framework
7.6.6.5. Reimbursement Scenario
7.6.6.6. Kuwait Nanomedicine Market, 2021 - 2033
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share Analysis, 2022
8.4. Company Profiles/Listing
8.4.1. Abbott Laboratories
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Combi Matrix Corporation
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Celgene Corporation
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Nano spectra Biosciences, Inc.
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. GE Healthcare
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Johnson & Johnson Services, Inc.
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Mallinckrodt Pharmaceuticals
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Merck & Co., Inc.
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Pfizer, Inc.
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Teva Pharmaceutical Industries Ltd.
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives
8.4.11. Arrowhead Pharmaceuticals, Inc.
8.4.11.1. Overview
8.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.11.3. Product Benchmarking
8.4.11.4. Strategic Initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers